J&J announces updated results from Phase 3 MARIPOSA-2 study

Johnson & Johnson announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVAN combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations. The data also reveal a favorable trend toward improved overall survival compared to chemotherapy alone. Results were presented at the European Society of Medical Oncology 2024 Congress. At the second interim analysis, with a median follow-up of 18.1 months, 50 percent of patients treated with RYBREVANT plus chemotherapy were still alive at the 18-month landmark, compared to 40 percent of those receiving chemotherapy alone. RYBREVANT plus chemotherapy showed a significant improvement in treatment discontinuation rates, with nearly five times as many patients remaining on therapy at 18 months compared to chemotherapy. Additionally, patients treated with RYBREVANT plus chemotherapy experienced a 27 percent reduction in the risk of symptomatic progression. The time to subsequent therapy was significantly prolonged with the RYBREVANT combination compared to chemotherapy, which also reduced the risk of second disease progression or death by 36 percent. In the MARIPOSA-2 study, the safety profile of RYBREVANT in combination with chemotherapy was consistent with the established profiles of the individual treatments. Permanent discontinuation of RYBREVANT due to adverse reactions occurred in 11 percent of patients. RYBREVANT(R) plus chemotherapy received approval by the European Commision in August 2024 as a treatment for patients with previously treated NSCLC with common EGFR mutations based on the superior efficacy and safety profile demonstrated in this study.